O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro

Pharmacological Research

Volumn 53, Issue 4, 2006, Pages 317-323

  Turriziani, M ^a   Caporaso, P ^b   Bonmassar, L ^b   Buccisano, F ^a   Amadori, S ^a   Venditti, A ^a   Cantonetti, M ^a   D'Atri, S ^b   Bonmassar, E ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c CNR   (Italy)

Author keywords

Leukaemia; O6 alkylguanine DNA alkyl transferase; PaTrin 2; Temozolomide

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE INHIBITOR; GUANINE DERIVATIVE; LOMEGUATRIB; TEMOZOLOMIDE; TRIAZENE DERIVATIVE; UNCLASSIFIED DRUG; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; GUANINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; O(6) (4 BROMOTHENYL)GUANINE; O(6)-(4-BROMOTHENYL)GUANINE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL STRAIN HL 60; CHEMOSENSITIVITY; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MISMATCH REPAIR; PHENOTYPE; PRIORITY JOURNAL; ACUTE DISEASE; BLOOD; CELL CULTURE; DRUG ANTAGONISM; DRUG POTENTIATION; ENZYMOLOGY; MONONUCLEAR CELL; MYELOID LEUKEMIA; PATHOLOGY;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DRUG SYNERGISM; GUANINE; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID; LEUKOCYTES, MONONUCLEAR; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TUMOR CELLS, CULTURED;

EID: 33646369663     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2005.12.001     Document Type: Article

References (54)

1. Franchi A., Papa G., D'Atri S., Piccioni D., Masi M., and Bonmassar E. Cytotoxic effects of dacarbazine in patients with acute myelogenous leukemia: a pilot study. Haematologica 77 (1992) 146-150
2. Seiter K., Liu D., Loughran T., Siddiqui A., Baskind P., and Ahmed T. Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol 20 (2002) 3249-3253
3. Seiter K., Liu D., Siddiqui A.D., Lerner R., Nelson J., and Ahmed T. Evaluation of temozolomide in patients with myelodysplastic syndrome. Leuk Lymphoma 45 (2004) 1209-1214
4. Atallah E., and Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 6 (2005) 185-193
5. Hoang-Xuan K., Camilleri-Broet S., and Soussain C. Recent advances in primary CNS lymphoma. Curr Opin Oncol 16 (2004) 601-606
6. Tani M., Fina M., Alinari L., Stefoni V., Baccarani M., and Zinzani P.L. Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. Haematologica 90 (2005) 1283-1284
7. Kanjeekal S., Chambers A., Fung M.F., and Verma S. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol 97 (2005) 624-637
8. Stupp R., van den Bent M.J., and Hegi M.E. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 5 (2005) 198-206
9. Chang S.M., Theodosopoulos P., Lamborn K., Malec M., Rabbitt J., Page M., et al. Temozolomide in the treatment of recurrent malignant glioma. Cancer 100 (2004) 605-611
10. Philip P.A., Souliotis V.L., Harris A.L., Salisbury A., Tates A.D., Mitchell K., et al. Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. Clin Cancer Res 2 (1996) 303-310
11. Tentori L., and Graziani G. Pharmacological strategies to increase the antitumor activity of methylating agents. Curr Med Chem 9 (2002) 1285-1301
12. Bodell W.J., Gaikwad N.W., Miller D., and Berger M.S. Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric brain tumors. Cancer Epidemiol Biomarkers Prev 12 (2003) 545-551
13. 6-methylguanine-DNA-transmethylase from rat liver. J Biol Chem 258 (1983) 2327-2333
14. 6-benzyl-guanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci 87 (1990) 5368-5372
15. Pegg A.E. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 462 (2000) 83-100
16. Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4 (2004) 296-307
17. Liu L., Markowitz S., and Gerson S.L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1.3-bis(2-chloroethyl)nitrosourea. Cancer Res 56 (1996) 5375-5379
18. Casorelli I., Offman J., Mele L., Pagano L., Sica S., D'Errico M., et al. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair (Amst) 2 (2003) 547-559
19. Papouli E., Cejka P., and Jiricny J. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res 64 (2004) 3391-3394
20. Fedier A., and Fink D. Mutations in DNA mismatch repair genes: implications for DNA damage signaling and drug sensitivity (review). Int J Oncol 24 (2004) 1039-1047
21. Son B.H., Ahn S.H., Ko C.D., Ka I.W., Gong G.Y., and Kim J.C. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. Breast J 10 (2004) 20-26
22. Trivedi R.N., Almeida K.H., Fornsaglio J.L., Schamus S., and Sobol R.W. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 65 (2005) 6394-6400
23. Morimoto H., Tsukada J., Kominato Y., and Tanaka Y. Reduced expression of human mismatch repair genes in adult T-cell leukemia. Am J Hematol 78 (2005) 100-107
24. 6-alkylguanine-DNA alkyltransferase deficient leukemic cell lines. Leukemia 9 (1995) 1885-1888
25. 6-alkylguanine-DNA alkyltransferase attenuates triazene induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia. Cancer Res 55 (1995) 6231-6236
26. Preuss I., Thust R., and Kaina B. Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int J Cancer 65 (1996) 506-512
27. Shiraishi A., Sakumi K., and Sekiguchi M. Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase. Carcinogenesis 21 (2000) 1879-1883
28. Kaina B., and Christmann M. DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther 40 (2002) 354-3567
29. 6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model. Int J Cancer 100 (2002) 615-617
30. 6-(hetarylmethyl)guanines having basic rings in the side chain. J Med Chem 41 (1998) 5265-5271
31. Chen J.M., Zhang Y.P., Moschel R.C., and Ikenaga M. Depletion of O6-methylguanine-DNA methyltransferase and potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea antitumor activity by O6-benzylguanine in vitro. Carcinogenesis 14 (1993) 1057-1060
32. (6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer 85 (2000) 248-252
33. 6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumor MCF-7 cells and xenograft. Br J Cancer 93 (2005) 1152-1156
34. Pearson S.J., Ferguson J., Santibanez-Koref M., and Margison G.P. Inhibition of O6-methylguanine-DNA methyltransferase by an alkyltransferase-like protein from Escherichia coli. Nucleic Acids Res 13 33 (2005) 3837-3844
35. Bobola M.S., Silber J.R., Ellenbogen R.G., Geyer J.R., Blank A., and Goff R.D. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines. Clin Cancer Res 11 (2005) 2747-2755
36. 6-alkylguanine-DNA alkyltransferase (ATase) depletion. Proc Am Assoc Cancer Res 41 (2000) abstract 3878
37. Woolford L.B., Southgate T.D., Margison G.P., Milsom M.D., and Fairbairn L.J. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine. J Gene Med. 8 (2005) 29-34
38. Barvaux V.A., Lorigan P., Ranson M., Gillum A.M., McElhinney R.S., McMurry T.B., et al. Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. Mol Cancer Ther 3 (2004) 1215-1220
39. Barvaux V.A., Ranson M., Brown R., McElhinney R.S., McMurry T.B., and Margison G.P. Dual repair modulation reverses temozolomide resistance in vitro. Mol Cancer Ther 3 (2004) 123-127
40. Pepponi R., Graziani G., Falcinelli S., Vernole P., Levati L., Lacal P.M., et al. hMSH3 overexpression and cellular response to cytotoxic anticancer agents. Carcinogenesis 22 (2001) 1131-1137
41. Matheson E.C., and Hall A.G. Assessment of mismatch repair function in leukaemic cell lines and blasts from children with acute lymphoid leukaemia. Carcinogenesis 24 (2003) 31-38
42. 6-methylguanine from DNA of normal and xeroderma pigmentosum-derived-lymphoblastoid lines. Nature 289 (1981) 417-420
43. di Pietro M., Marra G., Cejka P., Stojic L., Menigatti M., Cattaruzza M.S., et al. Mismatch repair-dependent transcriptome changes in human cells treated with the methylating agent N-methyl-n′-nitro-N-nitrosoguanidine. Cancer Res 63 (2003) 8158-8166
44. Giuliani A., Vernole P., D'Atri S., Del Poeta G., D'Onofrio C., Faraoni I., et al. In vitro infection of leukemic bone marrow with HTLV-I generates immortalized cell lines expressing T or myeloid cell phenotype. Leukemia 9 (1995) 2071-2081
45. Hansen M.B., Nielsen S.E., and Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119 (1989) 203-210
46. Morten J.E.N., and Margison G.P. Increased O6-alkylguanine alkyltransferase activity in Chinese hamster V79 cells following selection with chloroethylating agents. Carcinogenesis 9 (1988) 45-49
47. Zwaan C.M., Kaspers G.J., Pieters R., Hahlen K., Huismans D.R., Zimmermann M., et al. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 100 (2002) 3352-3360
48. Fureder W., Filipits M., Sperr W.R., Kainz B., Jager U., Fonatsch C., et al. Highly refractory acute myeloid leukemia. Wien Klin Wochenschr 116 (2004) 561-564
49. D'Atri S., Piccioni D., Castellano A., Tuorto V., Franchi A., Lu K., et al. Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann Oncol 6 (1995) 389-393
50. D'Atri S., Papa G., Tuorto V., Piccioni D., Franchi A., Del Poeta G., et al. O6-alkylguanine-DNA alkyltransferase activity in blasts obtained from patients with myelogenous or lymphocytic leukaemia. Pharmacol Res 26 Suppl. 2 (1992) 78-79
51. Gu L., Cline-Brown B., Zhang F., Qiu L., and Li G.M. Mismatch repair deficiency in hematological malignancies with microsatellite instability. Oncogene 21 (2002) 5758-5764
52. Casorelli I., Offman J., Mele L., Pagano L., Sica S., D'Errico M., et al. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair (Amst) 2 (2003) 547-559
53. Seedhouse C.H., Das-Gupta E.P., and Russell N.H. Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia. Leukemia 17 (Jan 2003) 83-88
54. Offman J., Opelz G., Doehler B., Cummins D., Halil O., Banner N.R., et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 104 (2004) 822-828